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Studies have shown that exposure to mercury can cause changes in the cardiovascular system, such as systemic arterial hypertension, coronary dysfunction, cardiac arrhythmia, and increase the risk of myocardial infarction. 3, 4 In humans, high blood mercury levels were correlated with increased systolic and diastolic blood pressure. 5 Mercury interference can also be observed in several enzymatic, amino acid and antioxidant reactions (N-acetyl-Lcysteine, alpha-lipoic acid, L-glutathione), reducing oxidative defense and increasing free radicals with consequent increase of oxidative stress. It is also possible that mercury may lead to mitochondrial dysfunction, causing glutathione depletion and rise on lipid peroxidation. 6 The study by Vassallo et al. 7 investigated if the chronic exposure to inorganic mercury increases the activity of the angiotensin converting enzyme (ACE) and its relation with oxidative stress in various organs and tissues from hypertensive and normotensive rats. Few studies have evaluated the chronic effects of low doses of inorganic mercury on the ACE activity in organs and tissues of normotensive and hypertensive animals.
The experimental model used by the author was the spontaneously hypertensive rat (SHR), which exhibits hypertension similar to human hypertension and has been widely used in several studies for analysis of cardiovascular and biochemical alterations. [7] [8] [9] The hemodynamic evaluation performed in the study by Vassallo et al. 7 showed that chronic exposure to mercury increased blood pressure in hypertensive animals and left ventricular end-diastolic pressure in normotensive animals. The biometry of the animals demonstrates that hypertensive rats have lower body weight than normotensive animals, data similar to those are found in the literature. 9, 10 The ratio of the brain and lungs normalized by body weight have significantly higher values in hypertensive animals. The weight ratio of the lungs normalized by body weight has been used as a marker of heart failure. 11 However, exposure to mercury did not cause biometric changes, except for those resulting from the hypertension factor.
Another interesting result shown by Vassallo et al. 7 was that the concentration of malondialdehyde (MDA) in normotensive animals treated with mercury had higher values in the plasma and the heart, and reduction was reduced in the kidneys. In hypertensive animals treated with mercury, the MDA concentration values are increased in the heart and aorta, and they are reduced in the lungs, brain and kidneys.
The ACE activity in Wistar animals treated with mercury presented higher values only in plasma and heart. Hypertensive animals treated with mercury presented higher values only in plasma and reduced values in the heart, aorta, lungs, brain and kidneys.
Therefore, exposure to mercury caused more significant changes in ACE activity and oxidative stress in SHR rats, determining specific alterations in each organ evaluated and representing a cardiovascular risk factor. The treatment of the animals with mercury exhibited at the end of the experimental period levels similar to those observed in humans exposed to the metal. 12 However, some questions related to the changes in ACE activity and oxidative stress caused by exposure to mercury are still unclear. More studies are needed to clarify, for example, whether mercury exposure could inhibit ACE activity in situations where it is already elevated, or whether preexisting cardiovascular disease would be aggravated by exposure to mercury.
